Catheter-directed thrombolytic therapy in peripheral artery occlusions: Combining reteplase and abciximab

American Journal of Roentgenology

Volumn 180, Issue 5, 2003, Pages 1385-1391

  Drescher, Peter ^a,b   McGuckin, James ^c   Rilling, William S ^a   Crain, Martin R ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Great Lakes Radiologists   (United States)

^c OUR LADY OF LOURDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLASMINOGEN ACTIVATOR; RETEPLASE;

ADULT; AGED; AMPUTATION; ANAMNESIS; ANGIOPLASTY; ARTICLE; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EMBOLECTOMY; FEASIBILITY STUDY; FEMALE; FIBRINOLYTIC THERAPY; GRAFT OCCLUSION; HEMATOMA; HEMATURIA; HEMOPTYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PETECHIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 0242600612     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.180.5.1801385     Document Type: Article

References (28)

1. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI 14 trial. Circulation 2000;101:239-243
2. [No authors listed] Trial of abciximab with and without low-dose reteplase for acute myocardial infarction: strategies for Patency Enhancement in the Emergency Department (SPEED) group. Circulation 2000;101:2788-2794
3. Schweitzer J, Kirch W, Koch R, Mueller A, Hellner G, Forkmann L. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis in patients with peripheral arterial occlusive disease and arterial thrombolysis. Angiology 2000;31:913-923
4. Tepe G, Schott U, Erley CM, Albes J, Claussen CD, Duda SH. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. AJR 1999;172:1343-1346
5. Drescher P, Crain MR, Rilling WS. Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study. J Vasc Interv Radiol 2002;13:37-43
6. Duda SH, Tepe G, Luz O, et al. Peripheral arterial occlusion: treatment with abciximab plus urokinase versus with urokinase alone - a randomized pilot trial (the PROMPT study). Radiology 2001;221:689-696
7. Hartnell GG, Gates J. The case of abbokinase and the FDA: the events leading to the suspension of abbokinase supplies in the United States. J Vasc Interv Radiol 2000;11:841-847
8. Patel N, Sacks D, Patel RI, et al. SCVIR reporting standard for the treatment of acute limb ischemia with the use of transluminal removal of arterial thrombus. J Vase Interv Radiol 2001;12:559-570
9. Rutherford BB, Becker GJ. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. J Vasc Surg 1997;26:517-538
10. Miller JM, Smalling R, Ohman EM, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Am J Cardiol 1999;84:779-784
11. [No authors listed] Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg 1994;220:251-268
12. Ouriel K, Veith F, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998;338:1105-1111
13. Verstraete M, Liijnen HR, Collen D. Thrombolytic agents in development. Drugs 1995;50:29-42
14. Martin U, von Mollendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.622 in healthy volunteers. Thromb Haemost 1991;66:569-574
15. Meierhenrich R, Carlsson J, Seifried E, et al. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency. Int J Cardiol 1998;65:57-63
16. Davidian M, Powell A, Benenati JF, Katzen BT, Becker GJ, Zemel G. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions. J Vasc Interv Radiol 2000;11:289-294
17. Ouriel K, Katzen BT, Mewissen M, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 2000;11:849-854
18. Pereira H. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Rev Port Cardiol 2001;20:687-688
19. Drescher P, Ong S, Rilling WS, Crain MR. Comparison of laboratory value changes and transfusion requirements in different thrombolytic regimens. (abstr) J Vasc Interv Radiol 2002;13[suppl]:S112
20. Semba CP, Murphy TP, Bakal CW, Callis KA, Matalon TA. Thrombolytic therapy with use of alteplase (t-PA) in peripheral arterial occlusive disease: review of the clinical literature. J Vasc Interv Radiol 2000;11:149-161
21. Ouriel K, Gray B, Clair DG, Olin J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed arterial and venous thrombolysis. J Vasc Interv Radiol 2000;11:295-298
22. Thomas SM, Gaines PA. Vascular Surgical Society of Great Britain and Ireland: avoiding the complications of thrombolysis. Br J Surg 1999;86:710-719
23. Decrinis M, Pilger E, Stark G, Lafer M, Obemosterer A, Lammer J. A simplified procedure for intraarterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results. Eur J Heart 1993;14:297-305
24. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000;140:206-211
25. Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 1989;79:920-928
26. Owen J, Friedmand KD, Grossman BA, et al. Thrombolytic therapy with tissue plasminogen activator and streptokinase induces transient thrombin activity. Blood 1988;72:616-620
27. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation 1997;95:1755-1759
28. Diffin DC, Kandarpa K. Assessment of peripheral arterial thrombolysis versus surgical revascularization in acute lower limb ischemia: a review of limb-salvage and mortality statistics. J Vasc Interv Radiol 1996;7:57-63